By: Jeff Minerd From: medpagetoday.com Clinical trial focused exclusively on TNBC patients Current breast cancer treatment guidelines suggest that capecitabine (Xeloda) should be considered for adjuvant treatment after standard neoadjuvant therapy with taxane- and anthracycline-based chemotherapy. However, although randomized trials have evaluated capecitabine as adjuvant treatment in breast cancer overall as well as in elderly patients, none have focused solely …
Nurse-Led Cognitive Behavioral Therapy Program Aids Management of Hot Flushes in Women With a History of Breast Cancer
By: Susan Moench, PhD, PA-C From: oncologynurseadvisor.com Patients with a history of breast cancer experiencing hot flushes and night sweats (HFNS) reported significant improvement in related quality-of-life measures following a nurse-led cognitive behavioral therapy (CBT) intervention compared with usual care, according to results of a randomized clinical trial published in Psycho-Oncology. Hot flushes and night sweats (HFNS) are commonly experienced …
Just a little physical activity pays big dividends to high risk breast cancer patients
By: SWOG From: medicalxpress.com Results of a comprehensive analysis of exercise and its protective role for high-risk breast cancer patients show that women who exercise not only live longer, but also are more likely to remain cancer-free after their treatment. What’s more, the study suggests that even a modest amount of exercise can be beneficial. “Aiming for as little as …
First Trial of Immunotherapy in Early-Stage Triple-Negative Breast Cancer Shows Promising Results
By: Danielle Ternyila From: targetedonc.com In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the findings from the interim analysis for the phase III KEYNOTE-522 study, which added pembrolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer. The randomized, phase III KEYNOTE-522 clinical trial evaluated the benefit of adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to …
Phase III trial evaluating Libtayo in NSCLC halted because of significant OS improvemen
From: cancerletter.com The primary endpoint of overall survival was met in a phase III trial comparing the PD-1 inhibitor Libtayo (cemiplimab) to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer who tested positive for PD-L1 in ≥50% of tumor cells. Libtayo is jointly developed and commercialized by Regeneron and Sanofi under a global collaboration …
Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment
By: Brittany Lovely From: onclive.com The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians. Bevacizumab (Avastin) continues to hold the most utility in this disease setting, but the addition of PARP inhibitors, and immunotherapy raises the question of how to best deliver efficient regimens to patients. …
FDA Approves Niraparib for Advanced Ovarian Cancer
By: Hannah Slater From: cancernetwork.com The FDA approved niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1 Efficacy for the agent was investigated in the double-blind placebo-controlled phase III PRIMA trial, designed to evaluate niraparib, versus placebo, in …
Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond
By: Ellie Leick From: onclive.com The use of PARP inhibitors has greatly expanded in the treatment of patients with BRCA-mutated breast cancer in recent years, according to Melinda L. Telli, MD, and research efforts are now examining these agents in novel combinations and beyond the BRCA setting. In January 2018, olaparib (Lynparza) joined the treatment arsenal for use as a …
Application of Neratinib in Breast Cancer Broadens
From: Rachel Narozniak, MA From: onclive.com The recent approval of neratinib (Nerlynx) in combination with capecitabine (Xeloda) for patients with late-stage, heavily pretreated HER2-positive breast cancer expanded the therapy’s established role in this disease setting. Neratinib was initially approved in July 2017 for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab (Herceptin)-based therapy.1 …
European Commission Approves Takeda’s Alunbrig for First-Line ALK-positive Lung Cancer
By: Staff Reporter From: precisiononcologynews.com Japan-based pharmaceutical company Takeda today announced that the European Commission has approved its selective tyrosine kinase inhibitor brigatinib (Alunbrig) as a monotherapy for patients with ALK-positive, advanced non-small cell lung cancer as a first-line option. The approval presents another treatment option for patients with ALK rearrangements, who make up three-to-five percent of all patients with …